Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Passage Bio, Inc. - Common Stock (NQ: PASG )

0.3920 -0.0080 (-2.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 427,081
Open 0.4100
Bid (Size) 0.3701 (5)
Ask (Size) 0.4300 (70)
Prev. Close 0.4000
Today's Range 0.3520 - 0.4289
52wk Range 0.3801 - 1.690
Shares Outstanding 61,767,286
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire

Performance

YTD
-52.77%
-52.77%
1 Month
-31.24%
-31.24%
3 Month
-48.28%
-48.28%
6 Month
-48.83%
-48.83%
1 Year
-70.75%
-70.75%

More News

Read More
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
From Passage Bio
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
From Passage Bio
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
From Passage Bio
Via GlobeNewswire
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
From Passage Bio
Via GlobeNewswire
Passage Bio Welcomes Tom Kassberg to Board of Directors
From Passage Bio
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Passage Bio
Via GlobeNewswire
PASG Stock Earnings: Passage Bio Beats EPS for Q2 2024
Via InvestorPlace
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Participate in Upcoming Investor Conferences
From Passage Bio
Via GlobeNewswire
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
From Passage Bio
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
From Passage Bio
Via GlobeNewswire
PASG Stock Earnings: Passage Bio Beats EPS for Q1 2024
Via InvestorPlace
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
From Passage Bio
Via GlobeNewswire
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Passage Bio
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.